Jun 21, 2021
Immutep to Evaluate Efti in Triple Combination Therapy Phase I Study with Chemotherapy and an anti-PD-1 Therapy
Jun 07, 2021
Immutep Reveals a New anti-LAG-3 Research Program
Jun 04, 2021
Immutep Reports Positive Data from its TACTI-002 Phase II Study of LAG-3 Therapy, Efti, at ASCO 2021
Immutep Reports Positive Final Data from the INSIGHT-004 Phase I Study of LAG-3 Therapy, Efti, at ASCO 2021
Jun 02, 2021
Immutep Secures Second European Patent For Eftilagimod Alpha, A Soluble LAG-3 Protein, In Combination With A PD-1 Pathway Inhibitor
May 31, 2021
Immutep Enters into a New Collaboration with Merck KGaA, Darmstadt, Germany for LAG-3 Therapy, Efti
May 26, 2021
Immutep Granted Chinese Patent for Eftilagimod Alpha in Chemo-Immunotherapy Combination
May 24, 2021
Immutep to Present at the Jefferies Virtual Healthcare Conference
May 20, 2021
Immutep Announces Publication of TACTI-002 and INSIGHT-004 Abstracts for ASCO 2021 Annual Meeting
May 06, 2021
Immutep Operational Update
Apr 27, 2021
Immutep To Announce New TACTI-002 and INSIGHT-004 Data in Poster Presentations and Discussion at the ASCO 2021 Annual Meeting
Apr 18, 2021
Immutep Quarterly Activities Report
